TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01391039
Drug: Perflutren lipid microsphere
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of 10 microL/kg once prior to ultrasound examination
Study: NCT01911598
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be administered as per schedule specified in the respective arm.
Study: NCT01911598
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered as per schedule specified in the respective arm.
Study: NCT01911598
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered as per schedule specified in the respective arm.
Study: NCT02130869
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV - All groups.
Study: NCT01911598
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered as per schedule specified in the respective arm.
Study: NCT01375088
Drug: propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
Study: NCT04133051
Drug: Quadratus Lumborum Block Using Bupivacaine 0.2%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block
Study: NCT02130869
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV - Group B only.
Study: NCT02130869
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
Study: NCT02130869
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV - Group B only.
Study: NCT02130869
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV - Group C only.
Study: NCT02130869
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
Study: NCT00790829
Drug: transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
Study: NCT01929889
Drug: Iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
Study: NCT04737187
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered every 2 weeks (Day 1 and Day 15)
Study: NCT00067262
Drug: Divalproex Sodium Extended-Release Tablets
Normalized name: Divalproex Sodium Extended-Release Tablets
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03478423
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study: NCT00159692
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02437253
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
Study: NCT00760773
Drug: Lacidophil (experimental high dose)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
Study: NCT02273401
Drug: BI 11054 CL
Normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098501
Drug: pelitinib
Normalized name: Pelitinib
DrugBank: Pelitinib (DB05524)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098501
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03694275
Drug: Soticlestat
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 tablets
Study: NCT05200169
Drug: 14C-AB1010
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
Study: NCT00325169
Drug: Tiotropium + SERETIDE 50/500
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03394001
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of 1% Lidocaine solution
Study: NCT03394001
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL of saline with 30 mg ketorolac
Study: NCT02455154
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole endocrine therapy for 2.5mg qd po.
Study: NCT03695237
Drug: Leuprolide Acetate (LA)
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intramuscularly as an injection
Study: NCT02772419
Drug: benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC administration
Study: NCT03478423
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study: NCT04068766
Drug: 5% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT03964207
Drug: Tiotropium Respimat® (T1)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation solution
Study: NCT03964207
Drug: Tiotropium Handihaler® (T2)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder
Study: NCT02022358
Drug: Glucarpidase
Normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucarpidase rescue (50 units/kg x 1, intravenously)
Study: NCT02022358
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
Study: NCT01003106
Drug: Ranibizumab 0.5mg (monthly)
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
Study: NCT01003106
Drug: Ranibizumab 2.0mg (monthly)
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02110719
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02110719
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02110719
Drug: percocet
Normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01003106
Drug: Pro re nata (prn) ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00506285
Drug: Methylphenidate Transdermal System (MTS)
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
Study: NCT02110719
Drug: vicodin
Normalized name: Vicodin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02110719
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00809796
Drug: pentamidine
Normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
Study: NCT02110719
Drug: dilaudid
Normalized name: Dilaudid
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02110719
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02110719
Drug: zofran
Normalized name: Zofran
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03607422
Drug: Placebo for Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally once a day
Study: NCT03607422
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally once a day
Study: NCT01968421
Drug: OM-85 BV
Normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
Study: NCT02047578
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT01082029
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
Study: NCT03541174
Drug: Aprocitentan 12.5 mg
Normalized name: aprocitentan 12.5 MG
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use
Study: NCT03541174
Drug: Aprocitentan 25 mg
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use
Study: NCT03224923
Drug: Ticagrelor 60mg
Normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily
Study: NCT03224923
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once daily
Study: NCT03224923
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily
Study: NCT00233870
Drug: Agalsidase beta (recombinant form)
Normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
Study: NCT00903604
Drug: AP214
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three 10-minutes infusions of sequential ascending dosages of AP214
Study: NCT00772798
Drug: Paclitaxel, Carboplatin and Vorinostat
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
Study: NCT00872989
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00872989
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01591148
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
Study: NCT04447859
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
Study: NCT00833833
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
Study: NCT00833833
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dexamethasone
Study: NCT00833833
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
Study: NCT02981108
Drug: HS-10296
Normalized name: HS-10296
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
Study: NCT02751411
Drug: Macrogol 4000
Normalized name: Macrogol 4000
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool softener
Study: NCT04049734
Drug: oral losatan
Normalized name: losartan Oral Tablet
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of oral losartan one hour before the ERCP once
Study: NCT00159133
Drug: antipsychotics vs. Lorazepam (Drugs)
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
Study: NCT02576301
Drug: Phase 1 - OXi4503 + cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Determination of MTD of the combination of OXi4503 + cytarabine
Study: NCT02576301
Drug: Phase 2 - OXi4503 + cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
Study: NCT02576301
Drug: Phase 2 - OXi4503 + cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
Study: NCT00201786
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
Study: NCT04027192
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg per day, orally
Study: NCT00416832
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01530542
Drug: oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone hydrochloride 5 mg tablet under fasted conditions
Study: NCT01530542
Drug: oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
Study: NCT01530542
Drug: oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
Study: NCT01530542
Drug: oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
Study: NCT01530542
Drug: marketed oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x oxycodone hydrochloride 15 mg tablet under fed conditions
Study: NCT00416832
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416832
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00416832
Drug: procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00416832
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04552483
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
Study: NCT03456661
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
Study: NCT03456661
Drug: Levobupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
Study: NCT02294162
Drug: Ketamine i.v
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00650351
Drug: Ciprofloxacin Extended-Release Tablets 1000 mg
Normalized name: ciprofloxacin Extended Release Oral Tablet
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT06106932
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
Study: NCT03053739
Drug: Sildenafil 20mg and Bosentan 62.5mg
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
Study: NCT03053739
Drug: Sildenafil 20mg and Placebo
Normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
Study: NCT00641329
Drug: CLONICEL (clonidine HCl sustained release)
Normalized name: clonidine hydrochloride Extended Release Suspension
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible Dose (0.1 - 0.4 mg)
Study: NCT02351934
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02351934
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
Study: NCT01630746
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no